在一名经组织学下一代测序（NGS）检测发现存在两种不同改变的奥希替尼耐药非小细胞肺癌（NSCLC）患者中使用卡马替尼治疗。 - Suppr

Suppr

超能文献

Capmatinib treatment in a patient with osimertinib-resistant NSCLC harboring two distinct alterations revealed by tissue-based NGS testing.

作者信息

Lausoontornsiri Wirote, Tan Chek Kun, Rajgor Dimple, Tang Yew Chung

机构信息

Department of Medical Oncology, Samitivej Sukhumvit Hospital, Bangkok 10110, Thailand.

Medical and Scientific Affairs, Mirxes 138622, Singapore.

出版信息

Cancer Pathog Ther. 2024 Dec 31;3(4):357-360. doi: 10.1016/j.cpt.2024.12.005. eCollection 2025 Jul.

DOI:10.1016/j.cpt.2024.12.005

PMID:40697513

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12277845/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1591/12277845/b81ed18eabfa/gr1.jpg

相似文献

Capmatinib treatment in a patient with osimertinib-resistant NSCLC harboring two distinct alterations revealed by tissue-based NGS testing.

Cancer Pathog Ther. 2024 Dec 31;3(4):357-360. doi: 10.1016/j.cpt.2024.12.005. eCollection 2025 Jul.

MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.

Aging (Albany NY). 2021 Feb 17;13(5):6890-6903. doi: 10.18632/aging.202547.

FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation.

Clin Lung Cancer. 2025 Mar;26(2):152-157.e1. doi: 10.1016/j.cllc.2024.09.002. Epub 2024 Sep 20.

Intracranial response to capmatinib after progression on crizotinib in a patient with exon 14 skipping non-small cell lung cancer-a case report.

Transl Lung Cancer Res. 2024 Jul 30;13(7):1749-1755. doi: 10.21037/tlcr-23-769. Epub 2024 Jul 15.

Next-Generation Sequencing-Based Testing Among Patients With Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States: Predictive Modeling Using Machine Learning Methods.

JMIR Cancer. 2025 Jun 11;11:e64399. doi: 10.2196/64399.

Osimertinib-Induced Hepatitis Following Immunotherapy in a Patient with Lung Adenocarcinoma Harboring De Novo EGFR Exon 19 Deletion and T790M Mutations: A Case Report.

Reports (MDPI). 2025 Jun 26;8(3):101. doi: 10.3390/reports8030101.

Osimertinib and Capmatinib Combination Therapy to Overcome Y1003N-Mediated Resistance in -Mutant NSCLC: A Case Report.

JTO Clin Res Rep. 2022 Aug 5;3(10):100396. doi: 10.1016/j.jtocrr.2022.100396. eCollection 2022 Oct.

Silencing of LINC01278 promotes sensitivity of non-small cell lung cancer cells to osimertinib by targeting miR-324-3p/ZFX axis.

Cytotechnology. 2025 Feb;77(1):23. doi: 10.1007/s10616-024-00673-8. Epub 2024 Dec 19.

Efficacy of osimertinib resumption with dabrafenib and trametinib for elderly patients with EGFR-mutated lung adenocarcinoma harboring acquired BRAF V600E resistant mutation resistant to osimertinib.

Jpn J Clin Oncol. 2025 Jul 6;55(7):832-836. doi: 10.1093/jjco/hyaf059.

Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non-Small Cell Lung Cancer.

JAMA Netw Open. 2024 Nov 4;7(11):e2442970. doi: 10.1001/jamanetworkopen.2024.42970.

本文引用的文献

Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report.

Heliyon. 2023 Nov 18;9(11):e22515. doi: 10.1016/j.heliyon.2023.e22515. eCollection 2023 Nov.

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation.

Front Oncol. 2022 Oct 13;12:965741. doi: 10.3389/fonc.2022.965741. eCollection 2022.

A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid).

Clin Cancer Res. 2023 Apr 14;29(8):1506-1514. doi: 10.1158/1078-0432.CCR-22-1749.

Capmatinib in Exon 14-Mutated or -Amplified Non-Small-Cell Lung Cancer.

N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787.

Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance.

Cancer Cell. 2020 Apr 13;37(4):485-495. doi: 10.1016/j.ccell.2020.03.012.

Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.

N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

Br J Cancer. 2019 Oct;121(9):725-737. doi: 10.1038/s41416-019-0573-8. Epub 2019 Sep 30.

Acquired Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00011. Epub 2019 May 10.

Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy.

Nat Rev Cancer. 2018 Jun;18(6):341-358. doi: 10.1038/s41568-018-0002-y.

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.

J Mol Diagn. 2017 Jan;19(1):4-23. doi: 10.1016/j.jmoldx.2016.10.002.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验